The burgeoning landscape of therapeutic interventions for metabolic disorders has witnessed considerable attention focused on GLP-3 agonists and, more recently, the dual GIP and GLP-3 agonist retatrutide. While both classes demonstrate remarkable efficacy in supporting glycemic control and facilitating significant weight management, key variatio… Read More

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting significant weight loss – they exhibit intriguing variations in their… Read More